[go: up one dir, main page]

WO2012138809A1 - Utilisation de composés hétérocycliques en tant qu'inhibiteurs des kinases - Google Patents

Utilisation de composés hétérocycliques en tant qu'inhibiteurs des kinases Download PDF

Info

Publication number
WO2012138809A1
WO2012138809A1 PCT/US2012/032236 US2012032236W WO2012138809A1 WO 2012138809 A1 WO2012138809 A1 WO 2012138809A1 US 2012032236 W US2012032236 W US 2012032236W WO 2012138809 A1 WO2012138809 A1 WO 2012138809A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
pyrrolo
pyrazol
pyridine
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/032236
Other languages
English (en)
Inventor
Dawei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2012138809A1 publication Critical patent/WO2012138809A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel heterocyclic compounds which act as inhibitors of kinase and are useful in methods of treating, preventing or inhibiting proliferative diseases including cancer.
  • Protein kinases represent a large family of enzymes, which catalyze the phosphorylation of target protein substrates.
  • the phosphorylation is usually a transfer reaction of a phosphate group from ATP to the protein substrate.
  • Common points of attachment for the phosphate group to the protein substrate include, for example, a tyrosine, serine or threonine residue. Due to their activity in numerous cellular processes, protein kinases have emerged as important therapeutic targets.
  • Raf kinases a family of three serine/threonine kinases, are part of the ras-MAPK signaling cascade and phosphorylate MEK.
  • Raf- 1 (or C- Raf) is activated by GTP-bound Ras and recruited to the cell membrane.
  • Raf- 1 is also thought to be able to dimerize with wild type B-Raf in a Ras -dependent process.
  • B-raf is commonly mutated and thereby activated in many human cancers, the most frequent mutation being the V600E mutation of the kinase domain. While wild type B-Raf and Raf-1 are strongly activated by growth factor signals via Ras and Src, A-Raf is only modestly activated and has low basal activity. All three isoforms of Raf are considered to be oncogenic.
  • R 1 is hydrogen, or optionally substituted Ci -8 alkyl
  • R 2 and R 3 at each occurrence are independently selected from the group consisting of hydrogen, optionally substituted Ci -8 alkyl, and CF 3 ;
  • R 4 and R 5 at each occurrence are independently selected from the group consisting of hydrogen, halogen, CF 3 , and optionally substituted Ci -8 alkyl;
  • R 6 is CF 3 or -NR 8 S0 2 R 9 ;
  • R 7 is hydrogen or optionally substituted Ci_g alkyl
  • R 8 is hydrogen or optionally substituted Ci -8 alkyl
  • R 9 is optionally substituted Ci -8 alkyl
  • X is N or CH
  • n 1, 2, or 3.
  • R 1 is a hydrogen. In certain embodiments, R 1 is a methyl group. In other embodiments, R 1 is an ethyl group. In certain embodiments, R 1 is a propyl group. In other embodiments, R 2 or R 3 is hydrogen. In some embodiments, R 2 or R 3 is trifluoromethyl group. In certain embodiments, R 4 or R 5 is CI. In some embodiments, R 4 or R 5 is F. In some embodiments, R 4 is F and R 5 is CI. In some embodiments, R 6 is an n-propyl sulfonamide. In other embodiments, R 7 is hydrogen. In certain embodiments, R 8 is hydrogen. In some embodiments, R 9 is n-propyl or deutered n-propyl. In some
  • X is -CH or nitrogen.
  • n is 2.
  • the compound of Formula I is in the form of pharmaceutically acceptable salt.
  • the compound of Formula I is a hydrochloride, or methanesulfonate salt.
  • the compound of Formula I is in the form of a solvate.
  • the compound of Formula I is in the form of a metabolite.
  • the compound of Formula I is in the form of a prodrug.
  • the compound of Formula I is an enantiomer.
  • the compound of Formula I is a diastereomer.
  • the deuterium enrichment in compounds of Formula I is at least about 1%.
  • the selected compound is in the form of a pharmaceutically acceptable salt.
  • the selected compound is a hydrochloride, or methanesultonate salt.
  • the selected compound is in the form of a solvate.
  • the selected compound is in the form of a metabolite.
  • the selected compound is in the form of a prodrug.
  • the selected compound has isotopic enrichment. In another embodiment, the deuterium enrichment in the selected compounds is at least about 1%.
  • compositions comprising a compound of formula I and a pharmaceutically acceptable carrier.
  • the compositions are for the treatment of a disease regulated by a protein kinase.
  • the compositions are for or the treatment of a hyper-proliferative disorder and/or angiogenesis disorder.
  • the pharmaceutical compositions further comprise an anti-neoplastic agent, an immunosuppressant, an immunostimulant, or combination thereof.
  • the pharmaceutical compositions are suitable for oral, parenteral, or intravenous administration.
  • the present invention provides methods for regulating the kinase signaling transduction, said method comprising administrating to a mammalian subject a therapeutically effective amount of a compound of Formula I.
  • a Raf including all mutant kinases
  • c-Met including all mutant kinases
  • MEK kinases including all mutant kinases
  • Alk mediated disorder said method comprises administrating to a mammalian subject a therapeutically effective amount of a compound of Formula I.
  • methods for treating or preventing a Raf V600E mutation mediated disorder comprises administrating to a mammalian subject a therapeutically effective amount of a compound of Formula I.
  • neoplasia comprising administrating to a mammalian subject in need thereof, a therapeutically effective amount of a compound of Formula I.
  • the neoplasia is selected from skin cancer, leukemias, colon carcinoma, renal cell carcinoma, gastrointestinal stromal cancer, solid tumor cancer, myeloma, breast cancer, pancreatic carcinoma, non-small cell lung cancer, non-hodgkin' s lymphoma, hepatocellular carcinoma, thyroid cancer, bladder cancer, colorectal cancer, and prostate cancer.
  • the neoplasia is skin cancer.
  • the methods further comprise administering one or more anticancer agents.
  • methods for treating or preventing a hyper-proliferative and/or angiogenesis comprising administrating to a mammalian subject a therapeutically effective amount of a compound of Formula I.
  • Optionally substituted alkyl means that each hydrogen in the alkyl group (usually Ci-C 8 ) is substituted by none, one or more halogen, hydroxyl, Ci-C 6 alkoxy, etc.
  • Alkyl group can be either straight or branched.
  • Halogen means fluorine, chlorine, bromine, and iodine.
  • isotopic enrichment means the isotopic abundance over the natural abundance of a specified isotope.
  • the invention also includes isotopically-labeled compounds of the invention, wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as deuterium, and carbon, such as 13 C.
  • Certain isotopically-labeled compounds of the invention for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements; and hence may be preferred in some circumstances.
  • a pharmaceutically acceptable when used with reference to a compound of Formula I is intended to refer to a form of the compound that is safe for administration to a subject.
  • a free base, a salt form, a solvate, a hydrate, a prodrug or derivative form of a compound of Formula I which has been approved for mammalian use, via oral ingestion or any other route of administration, by a governing authority or regulatory agency, such as the Food and Drug Administration (FDA) of the United States, is pharmaceutically acceptable.
  • FDA Food and Drug Administration
  • salts Included in the compounds of Formula I are the pharmaceutically acceptable salt forms of the free-base compounds.
  • pharmaceutically-acceptable salts embraces salts, commonly used to form alkali metal salts and to form addition salts of free acids or free bases, which have been approved by a regulatory agency. Salts are formed from ionic associations, charge-charge interactions, covalent bonding, complexation, coordination, etc. The nature of the salt is not critical, provided that it is pharmaceutically acceptable.
  • derivative is broadly construed herein, and intended to encompass any salt of a compound of this invention, any ester of a compound of this invention, or any other compound, which upon administration to a patient is capable of providing (directly or indirectly) a compound of this invention, or a metabolite or residue thereof, characterized by the ability to modulate a kinase enzyme.
  • prodrug denotes a compound which upon
  • prodrugs would include esterified or hydroxylated compounds where the ester or hydroxyl groups would cleave in vivo, such as in the gut, to produce a compound according to Formula I.
  • the compound(s) of Formula I is used to treat a subject by administering the compound(s) as a pharmaceutical composition.
  • the compound(s) in one embodiment, is combined with one or more pharmaceutically acceptable excipients, including carriers, diluents or adjuvants, to form a suitable composition, which is described in more detail herein.
  • treat refers to therapy, including without limitation, curative therapy, prophylactic therapy, and preventative therapy.
  • Prophylactic treatment generally constitutes either preventing the onset of disorders altogether or delaying the onset of a pre-clinically evident stage of disorders in individuals.
  • the phrase "effective amount" is intended to quantify the amount of each agent, which will achieve the goal of improvement in disorder severity and the frequency of incidence over treatment of each agent by itself, while avoiding adverse side effects typically associated with alternative therapies.
  • the effective amount in one embodiment, is administered in a single dosage form or in multiple dosage forms.
  • the ability of the solvent to allow and/or influence the progress or rate of the reaction is generally dependant on the type and properties of the solvent(s), the reaction conditions including temperature, pressure, atmospheric conditions such as in an inert atmosphere under argon or nitrogen, and concentration, and of the reactants themselves.
  • the invention further encompasses "intermediate" compounds, including structures produced from the synthetic procedures described, whether isolated or not, prior to obtaining the finally desired compound. Structures resulting from carrying out steps from a transient starting material, structures resulting from divergence from the described method(s) at any stage, and structures forming starting materials under the reaction conditions are all
  • the compounds of this invention in some embodiments also are represented in multiple tautomeric forms.
  • the invention expressly includes all tautomeric forms of the compounds described herein.
  • the compounds in one embodiment also occur in cis- or trans- or E- or Z- double bond isomeric forms. All such isomeric forms of such compounds are expressly included in the present invention. All crystal forms of the compounds described herein are expressly included in the present invention.
  • kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log -phase, infected with T7 phage and incubated with shaking at 32 °C until lysis. The lysates were centrifuged and filtered to remove cell debris. The remaining kinases were produced in HEK-293 cells and subsequently tagged with DNA for qPCR detection. Streptavidin-coated magnetic beads were treated with biotinylated small molecule ligands for 30 minutes at room temperature to generate affinity resins for kinase assays.
  • Binding reactions were assembled by combining kinases, liganded affinity beads, and test compounds in lx binding buffer (20% SeaBlock, 0.17x PBS, 0.05% Tween 20, 6 mM DTT). All reactions were performed in polystyrene 96-well plates in a final volume of 0.135 ml.
  • the assay plates were incubated at room temperature with shaking for 1 hour and the affinity beads were washed with wash buffer (lx PBS, 0.05% Tween 20). The beads were then re-suspended in elution buffer (lx PBS, 0.05% Tween 20, 0.5 ⁇ non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 minutes. The kinase concentration in the eluates was measured by qPCR.
  • the assay was performed using Kinase-Glo ® Plus luminescent kinase assay kit (Promega). It measures kinase activity by quantitating the amount of ATP remaining in solution following a kinase reaction. The luminescent signal from the assay is correlated with the amount of ATP present and is inversely correlated with the amount of kinase activity.
  • the compounds were diluted in 10% DMSO and 5 ⁇ of the dilution was added to a 50 ⁇ reaction so that the final concentration of DMSO is 1 % in all of reactions. All of the enzymatic reactions were conducted at 30 °C for 40 minutes.
  • the 50 ⁇ reaction mixture contains 40 mM Tris, pH 7.4, 10 mM MgCl 2 , 0.1 mg/ml BSA, 1 mM DTT,
  • Base Reaction buffer 20 mM Hepes (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na 3 V0 4 , 2 mM DTT, 1% DMSO
  • Cell culture was purchased from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). The cell was cultured in DMEM(GIBCO) with 10% fetal bovine serum (GIBCO), 1% L-glutamine, 100 U/mL, penicillin G and 100 ⁇ g/mL streptomycin. Cells were incubated at 37°C in a humidified incubator with 5% CO 2 .
  • WST assay Inhibition of cell growth was determined by WST assay using Cell Counting Kit-8 (CCK-8) from DOJINDO Molecular Technologies, Inc. Cells were seeded in the 96-well plates and treated with different concentrations of compounds (dilute from 100 ⁇ /L) single for 72 h. Three repeat wells per treatment were required. After adding CCK-8 10 /L to each well of the plate, the plates were incubated at 37°C for 2 h. Then the absorbance at 450 nm was measured using the Spectra Max 190 (Molecular Devices) microplate reader. The tests were repeated once. The results were presented as IC50 of the compound. IC50 was calculated with Graphpad Prism software using nonlinear regression (curve fit) type data analysis.
  • Examples 4, 5, 6 have been tested in the kinase BRAF (V600E) assay and all of them having Kd less than 1 nM.
  • Example 14 had IC 50 less than 0.5 nM in the kinase BRAF (V600E) assay.
  • Example 14 has been tested in the BRAF wild type kinase assay and showed 5 times more potent than PLX4032.
  • Examples 4, 5, 6 and 14 have been tested in the A375 cell assay and all of them having IC50 less than 200 nM.
  • Example 4 is much more soluble than PLX4032 when they were measured in the common media such as PBS, 0.01N HC1 and SIF.
  • Compounds Kd against BRAF (V600E) are much more soluble than PLX4032 when they were measured in the common media such as PBS, 0.01N HC1 and SIF.
  • Example 4 Preparation of N-(2,4-difluoro-3-(5-(l-(piperidin-4-yl)-lH-pyrazol-4- yl) - 1 H-p yrrolo ⁇ 2 , 3 -bl pyridine- 3 -carbon yl)phenyl)propane- 1 -sulfonamide.
  • Step 1 Preparation of ferf-butyl 4-(4-(3-(2,6-difluoro-3-
  • the mixture was purged with bubbling nitrogen for 2 minutes, and then stirred at 100 °C overnight.
  • the reaction was cooled to room temperature, poured into water (100 mL), and extracted with ethyl acetate (6 x 50mL). The combined organic layers were washed with brine, dried over (MgS0 4 ), filtered, and concentrated.
  • Step 2 To a solution of ferf-butyl 4-(4-(3-(2,6-difluoro-3-
  • Step 2 2-Chloro-6-fluoro-3-nitrobenzoyl chloride.
  • 2-chloro-6-fluoro-3- nitrobenzoic acid 2.0 g
  • sulfurous dichloride 10 mL
  • the reaction mixture was heated to reflux and stirred for 2 hours. Then sulfurous dichloride was removed under vacuum.
  • the product example 9 was used in the next step without further purification.
  • Step 3 (5-Bromo-lH-pyrrolo[2,3-b]pyridin-3-yl)-(2-chloro-6-fluoro-3- nitrophenyl)methanone.
  • aluminum trichloride (6.8 g, 51.4 mmol, 5.7 eq) was added methylene chloride (50 mL) under an atmosphere of nitrogen below 5 °C.
  • 5-bromo -7-azaindole (1.27 g, 6.4 mmol, 0.71 eq) in methylene chloride (20 mL) was added.
  • reaction mixture was stirred for 1 hour and 2-chloro-6-fluoro-3-nitrobenzoyl chloride in methylene chloride (30 mL) was added.
  • the reaction mixture was stirred for 6 hours and warmed to room temperature overnight.
  • the reaction mixture was poured into water (500 mL) and extracted with ethyl acetate (150 mL x 3).
  • Step 4 (3-Amino-2-chloro-6-fluorophenyl)(5-bromo-lH-pyrrolo[2,3-b]pyridin-3- yl)methanone.
  • ethanol (10 ml) (1.6 g)
  • water (10 ml) and acetic acid (5 ml) were charged into a 50 ml single-neck round-bottom flask.
  • the reaction mixture was heated to reflux and stirred for 2 hours. Then the reaction mixture was cooled to rt.
  • the mixture was poured into water (50 ml) and extracted with ethyl acetate/THF (50 ml x 3, 1 : 1). Combined organic layers were dried over anhydrous sodium sulfate, filtrated and
  • Step 5 Propane 1 -sulfonylchloride was added dropwise (1 mL) to a solution of (3- amino-2-chloro-6-fluorophenyl)(5-bromo-lH-pyrrolo[2,3-b]pyridin-3-yl)methanone (l.Og), pyridine (3 ml), and DMAP (20 mg,) in anhydrous dichloromethane/THF (10/5 mL) at room temperature. Upon completion of the addition, the reaction mixture was refluxed overnight and evaporated in vacuum.
  • Example 14 The preparation of N-(2-chloro-4-fluoro-3-(5-(l-(piperidin-4-yl)-lH- pyrazol-4-yl)-lH-pyrrolo[2, -b]pyridine-3-carbonyl)phenyl)propane-l-sulfonamide.
  • Step 1 The preparation of ieri-butyl4-(4-(3-(2-chloro-6-fluoro-3- (propylsulfonamido)benzoyl) -lH-pyrrolo[2,3-b] pyridin-5-yl)-lH-pyrazol-l-yl)piperidine-l- carboxylate.
  • the mixture was purged with bubbling nitrogen for 2 min, and then stirred at 100 °C overnight, cooled to room temperature, poured into water (100 mL), and extracted with ethyl acetate (6 x 50mL), and the combined organic layers were washed with brine, dried (MgS04), filtered, and concentrated.
  • the crude product was purified by flash column chromatography on silica gel to give the desired product (500 mg).
  • Step 2 ieri-Butyl4-(4-(3-(2-chloro-6-fluoro-3-(propylsulfonamido)benzoyl)-lH- pyrrolo[2,3-b] pyridin-5-yl)-lH-pyrazol-l-yl)piperidine-l-carboxylate (500 mg) was dissolved with THF (5 ml). Then 15 ml saturated solution of 1,4-dioxane (HCl) was added to the reaction solution. The reaction mixture was stirred for 4 hours at rt. The solvent was removed under vacuum to give the desired product (400 mg).
  • the present invention provides compounds which are capable of modulating one or more signal transduction pathways comprising, but not limited to Raf kinase.
  • module it is meant that the functional activity of the pathway (or a component thereof) is changed in comparison to its normal activity in the absence of the compound. This effect includes any quality or degree of modulation, including, increasing, agonizing, augmenting, enhancing, facilitating, stimulating, decreasing, blocking, inhibiting, reducing, diminishing, and antagonizing, etc.
  • the compounds of the present invention can also modulate one or more of the following processes, including, but not limited to, e.g., cell growth (including, e.g., differentiation, cell survival, and/or proliferation), tumor cell growth (including, e.g., differentiation, cell survival, and/or proliferation), tumor regression, endothelial cell growth (including, e.g., differentiation, cell survival, and/or proliferation), angiogenesis (blood vessel growth), lymphangiogenesis (lymphatic vessel growth), and/or hematopoiesis ⁇ e.g., T- and B- cell development, dendritic cell development, etc.).
  • cell growth including, e.g., differentiation, cell survival, and/or proliferation
  • tumor cell growth including, e.g., differentiation, cell survival, and/or proliferation
  • tumor regression including, e.g., differentiation, cell survival, and/or proliferation
  • endothelial cell growth including, e.g., differentiation, cell survival, and/or proliferation
  • angiogenesis blood vessel
  • kinase activity it is meant a catalytic activity in which a gamma-phosphate from adenosine triphosphate (ATP) is transferred to an amino acid residue (e.g., serine, threonine, or tyrosine) in a protein substrate.
  • ATP adenosine triphosphate
  • a compound can modulate kinase activity, e.g., inhibiting it by directly competing with ATP for the ATP-binding pocket of the kinase, by producing a conformational change in the enzyme's structure that affects its activity (e.g., by disrupting the biologically-active three- dimensional structure), and by binding to and locking the kinase in an inactive conformation, etc.
  • Treatment of diseases and disorders herein is intended to also include therapeutic administration of a compound of the invention, or a pharmaceutical salt thereof, or a pharmaceutical composition of either to a subject (i.e. , an animal, preferably a mammal, most preferably a human) which may be in need of preventative treatment, such as, for example, for pain, inflammation and the like.
  • Treatment also encompasses prophylactic administration of a compound of the invention, or a pharmaceutical salt thereof, or a pharmaceutical composition of either to a subject (i.e. , an animal, preferably a mammal, most preferably a human).
  • the subject is initially diagnosed by a licensed physician and/or authorized medical practitioner, and a regimen for prophylactic and/or therapeutic treatment via administration of the compound(s) or compositions of the invention is suggested, recommended or prescribed.
  • the amount of compound(s) which is/are administered and the dosage regimen for treating cancer with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the type of disease, the severity of the disease, the route and frequency of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods.
  • a daily dose of about 0.01 to 500 mg/kg, advantageously between about 0.01 and about 50 mg/kg, more advantageously about 0.01 and about 30 mg/kg, even more advantageously between about 0.1 and about 10 mg/kg, and even more advantageously between about 0.25 and about 1 mg/kg body weight may be appropriate, and should be useful for all methods of use disclosed herein.
  • the daily dose can be administered in one to four doses per day.
  • the compound administered normally will be present as an active ingredient in a pharmaceutical composition.
  • a pharmaceutical composition comprising a compound of this invention in combination with a pharmaceutically acceptable carrier, which includes diluents, excipients, adjuvants and the like (collectively referred to herein as "carrier" materials) as described herein, and, if desired, other active ingredients.
  • carrier includes diluents, excipients, adjuvants and the like (collectively referred to herein as "carrier” materials) as described herein, and, if desired, other active ingredients.
  • a pharmaceutical composition of the invention may comprise an effective amount of a compound of the invention or an effective dosage amount of a compound of the invention.
  • An effective dosage amount of a compound of the invention includes an amount less than, equal to or greater than an effective amount of the compound; for example, a pharmaceutical composition in which two or more unit dosages, such as in tablets, capsules and the like, are required to administer an effective amount of the compound, or alternatively, a multi-dose pharmaceutical composition, such as powders, liquids and the like, in which an effective amount of the compound is administered by administering a portion of the composition.
  • Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ophthalmic, pulmonary, transmucosal, transdermal, vaginal, otic, nasal, and topical administration.
  • parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injections.
  • the compounds of the invention may be administered orally.
  • Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.
  • Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nanoparticulates, gels, solid solution, liposome, films (including muco-adhesive), ovules, sprays and liquid formulations.
  • Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be used as fillers in soft or hard capsules and typically include a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
  • a carrier for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil
  • emulsifying agents and/or suspending agents may also be prepared by the reconstitution of a solid, for example, from a sachet.
  • the compounds of the invention may also be used in fast-dissolving, fast- disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986 by Liang and Chen (2001), the disclosure of which is incorporated herein by reference in its entirety.
  • the drug may make up from 1 wt% to 80 wt% of the dosage form, more typically from 5 wt% to 60 wt% of the dosage form.
  • tablets generally contain a disintegrant.
  • disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinized starch and sodium alginate.
  • the disintegrant will comprise from 1 wt% to 25 wt%, preferably from 5 wt% to 20 wt% of the dosage form.
  • Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate. Tablets may also optionally include surface active agents, such as sodium lauryl sulfate and
  • polysorbate 80 polysorbate 80, and glidants such as silicon dioxide and talc.
  • surface active agents are 30 typically in amounts of from 0.2 wt% to 5 wt% of the tablet, and glidants typically from 0.2 wt% to 1 wt% of the tablet.
  • Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate.
  • Lubricants generally are present in amounts from 0.25 wt% to 10 wt%, preferably from 0.5 wt% to 3 wt% of the tablet.
  • Other conventional ingredients include anti-oxidants, colorants, flavoring agents, preservatives and taste-masking agents.
  • Exemplary tablets contain up to about 80 wt% drug, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about 10 wt% lubricant.
  • the final formulation may include one or more layers and may be coated or uncoated; or encapsulated.
  • the formulation of tablets is discussed in detail in
  • Solid formulations for oral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • the compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ.
  • Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous.
  • Suitable devices for parenteral administration include needle (including micro needle) injectors, needle-free injectors and infusion techniques.
  • Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
  • a suitable vehicle such as sterile, pyrogen-free water.
  • the preparation of parenteral formulations under sterile conditions for example, by lyophilization, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
  • solubility of compounds of the invention used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility enhancing agents.
  • Formulations for parenteral administration may be formulated to be immediate and/or modified release.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound. Examples of such formulations include drug-coated stents and PGLA microspheres.
  • the compounds of the invention can be dosed or administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or in conjunction with other agents.
  • the therapeutic agents can be formulated as separate compositions that are administered simultaneously or sequentially at different times, or the therapeutic agents can be given as a single composition.
  • methods for treatment of kinases mediated conditions or diseases, such as proliferative disorders, including cancer comprises administration to a mammal a compound of Formula I in combination with at least one additional agent selected, by way of example only, alemtuzumab, arsenic trioxide, asparaginase (pegylated or non-), bevacizumab, cetuximab, platinum-based compounds such as cisplatin, cladribine, daunorubicin/doxorubicin/idarubicin, irinotecan, fludarabine, 5-fluorouracil, gemtuzumab, methotrexate, taxol, temozolomide, thioguanine, or classes of drugs including hormones (an antiestrogen, an antiandrogen, or gonadotropin releasing hormone analogues, interferons such as alpha interferon, nitrogen mustards such as busulfan or melphalan or mech
  • additional agent selected, by way of

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne de nouveaux composés hétérocycliques de formule I jouant le rôle d'inhibiteurs des kinases et utilisés dans des méthodes de traitement, de prévention ou d'inhibition de maladies prolifératives, notamment le cancer.
PCT/US2012/032236 2011-04-05 2012-04-05 Utilisation de composés hétérocycliques en tant qu'inhibiteurs des kinases Ceased WO2012138809A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161516505P 2011-04-05 2011-04-05
US61/516,505 2011-04-05

Publications (1)

Publication Number Publication Date
WO2012138809A1 true WO2012138809A1 (fr) 2012-10-11

Family

ID=46969541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/032236 Ceased WO2012138809A1 (fr) 2011-04-05 2012-04-05 Utilisation de composés hétérocycliques en tant qu'inhibiteurs des kinases

Country Status (1)

Country Link
WO (1) WO2012138809A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103613591A (zh) * 2012-09-29 2014-03-05 天津滨江药物研发有限公司 作为cMet抑制剂的化合物及其制备方法和用途
EP2672967A4 (fr) * 2011-02-07 2014-08-20 Plexxikon Inc Composés et procédés de modulation de kinase, et leurs indications
US9096593B2 (en) 2009-11-06 2015-08-04 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9169250B2 (en) 2006-11-22 2015-10-27 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CN105384738A (zh) * 2014-08-21 2016-03-09 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253170B2 (en) * 2003-05-01 2007-08-07 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
US20090118305A1 (en) * 2007-10-25 2009-05-07 Astrazeneca Ab Pyridine and pyrazine derivatives - 083
US20090215788A1 (en) * 2008-02-25 2009-08-27 Todd Richard Elworthy Pyrrolopyrazine kinase inhibitors
US20090298820A1 (en) * 2008-05-28 2009-12-03 Wyeth 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US20100286142A1 (en) * 2009-05-06 2010-11-11 Ibrahim Prabha N Compounds and Methods for Kinase Modulation, and Indications Therefor
US20100310659A1 (en) * 2009-04-03 2010-12-09 Plexxikon, Inc. Compositions and Uses Thereof
US20110059963A1 (en) * 2005-06-22 2011-03-10 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US20110183988A1 (en) * 2009-12-23 2011-07-28 Ibrahim Prabha N Compounds and methods for kinase modulation, and indications therefor

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253170B2 (en) * 2003-05-01 2007-08-07 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
US20110059963A1 (en) * 2005-06-22 2011-03-10 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US20090118305A1 (en) * 2007-10-25 2009-05-07 Astrazeneca Ab Pyridine and pyrazine derivatives - 083
US20090215788A1 (en) * 2008-02-25 2009-08-27 Todd Richard Elworthy Pyrrolopyrazine kinase inhibitors
US7902197B2 (en) * 2008-02-25 2011-03-08 Roche Palo Alto Llc Pyrrolopyrazine kinase inhibitors
US20090298820A1 (en) * 2008-05-28 2009-12-03 Wyeth 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US20100310659A1 (en) * 2009-04-03 2010-12-09 Plexxikon, Inc. Compositions and Uses Thereof
US20100286142A1 (en) * 2009-05-06 2010-11-11 Ibrahim Prabha N Compounds and Methods for Kinase Modulation, and Indications Therefor
US20110183988A1 (en) * 2009-12-23 2011-07-28 Ibrahim Prabha N Compounds and methods for kinase modulation, and indications therefor

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169250B2 (en) 2006-11-22 2015-10-27 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9487515B2 (en) 2006-11-22 2016-11-08 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9663517B2 (en) 2009-04-03 2017-05-30 Plexxikon Inc. Compositions and uses thereof
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
US9096593B2 (en) 2009-11-06 2015-08-04 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2672967A4 (fr) * 2011-02-07 2014-08-20 Plexxikon Inc Composés et procédés de modulation de kinase, et leurs indications
US12076322B2 (en) 2011-02-07 2024-09-03 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US11337976B2 (en) 2011-02-07 2022-05-24 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9695169B2 (en) 2012-05-31 2017-07-04 Plexxikon Inc. Synthesis of heterocyclic compounds
CN103613591B (zh) * 2012-09-29 2016-04-13 上海科州药物研发有限公司 作为cMet抑制剂的化合物及其制备方法和用途
CN103613591A (zh) * 2012-09-29 2014-03-05 天津滨江药物研发有限公司 作为cMet抑制剂的化合物及其制备方法和用途
CN105384738A (zh) * 2014-08-21 2016-03-09 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Similar Documents

Publication Publication Date Title
CN105408334B (zh) 作为激酶抑制剂的取代的吡唑并嘧啶类化合物
EP2833886B1 (fr) Quinoléines substituées en tant qu'inhibiteurs de tyrosine kinase de bruton
US9550738B2 (en) Bicyclic compounds as kinases inhibitors
WO2012138809A1 (fr) Utilisation de composés hétérocycliques en tant qu'inhibiteurs des kinases
JP5581390B2 (ja) Ａｋｔ阻害剤
CN105085483B (zh) 激酶抑制剂及其应用
WO2018121228A1 (fr) Composé ayant une activité inhibitrice d'axl, sa méthode de préparation et son utilisation
JP5820080B2 (ja) 三環系ＰＩ３Ｋ及び／又はｍＴＯＲ抑制剤
WO2013041038A1 (fr) Composés de pyridine comme inhibiteurs de kinases
EP3661935B1 (fr) Pyrazolopyrimidines substituées pouvant être employées en tant qu'inhibiteurs de kinases
EP3844166B1 (fr) Macrocycles substitués utiles en tant qu'inhibiteurs de kinase
WO2012167606A1 (fr) Inhibiteurs doubles de pi3k/mtor de pyridonaphtyridine et préparation et utilisation de ceux-ci
US11427559B2 (en) Substituted quinolines useful as kinase inhibitors
US10173995B2 (en) Pyridine compounds used as PI3 kinase inhibitors
KR101796779B1 (ko) 다이하이드로프테리딘-온 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
WO2014139391A1 (fr) Utilisation de composés de pyridine substituée en tant qu'inhibiteurs de kinases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12767253

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12767253

Country of ref document: EP

Kind code of ref document: A1